Cristiane R. V. Castro
A5089524663- LGBTQ Health, Identity, and Policy
- HIV/AIDS Research and Interventions
- Sexuality, Behavior, and Technology
- Syphilis Diagnosis and Treatment
- Sex work and related issues
- African Sexualities and LGBTQ+ Issues
- Adolescent Sexual and Reproductive Health
- HIV, Drug Use, Sexual Risk
- Gender, Feminism, and Media
San Francisco Department of Public Health
2021
Fundação Oswaldo Cruz
2021
Trans women face disproportionate burden of adverse health outcomes, including mental issues. Very little is known about suicidal behavior among trans in low- and middle-income settings, such as Brazil. We aimed to estimate the prevalence lifetime identify its associated factors Brazilian women.This was a cross-sectional study conducted 345 living Rio de Janeiro, examined (ideation suicide attempt) using stepwise backward Poisson regression analysis with robust variance.Suicidal ideation...
Trans women are specifically vulnerable to interpersonal violence. Being perceived as the gender that a transgender person identifies with, defined in some contexts passing, may influence violence ratings. The EVAS (Violence and Health Self-Evaluation) study was cross-sectional enrolled 121 trans between 2019 2020 Rio de Janeiro, Brazil, aiming investigate association self-reported passing different types of We participants who had median age 36.3 (interquartile range [IQR] 13.7). Most them...
Abstract Objectives Potential interactions between feminizing hormone therapy (FHT) and pre-exposure prophylaxis (PrEP) may be a barrier to PrEP use among transgender women (TGW). We aimed assess the impact of FHT on plasma pharmacokinetics (PK) TGW. Methods This was PK substudy effects tenofovir disoproxil fumarate/emtricitabine nested trans-specific demonstration study (NCT03220152). Participants were assigned receive only (noFHT) or standardized (sFHT; oestradiol valerate 2–6 mg plus...
An important barrier to HIV prevention among transgender women (TGW) is the concern that oral pre-exposure prophylaxis (PrEP) negatively affects efficacy of feminizing hormone therapy (FHT). We aimed assess impact PrEP on FHT pharmacokinetics (PK) TGW from Brazil. performed a drug-drug interaction sub-study enrolled in daily demonstration study (PrEParadas, NCT03220152). Participants had first PK assessment (PK1) 15 days after (estradiol valerate 2–6 mg plus spironolactone 100–200 mg)...
Background This study aimed to determine the efficacy of an evidence-based peer and mHealth delivered systems navigation intervention for increasing human immunodeficiency virus (HIV) testing, pre-exposure prophylaxis (PrEP) HIV care behaviors among young trans women. Methods The “Brilhar e Transcender” (BeT) pilot was conducted between 19 September 2019 26 November 2020 in a trans-affirming public health clinic Rio de Janeiro, Brazil. Participants were recruited using convenience sampling...